Cargando…

Successful Treatment of Ocular Chronic Lymphocytic Leukemia with Ibrutinib: Case Report and Review of the Literature

Detalles Bibliográficos
Autores principales:	Chauhan, Ayushi F, Viruni, Narine, Alvin Liu, T.Y., Arevalo, J Fernando, Cheson, Bruce D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265052/ https://www.ncbi.nlm.nih.gov/pubmed/32509518 http://dx.doi.org/10.1016/j.lrr.2020.100200

Ejemplares similares

Ocular involvement in TEMPI syndrome
por: Wu, Jo-Hsuan, et al.
Publicado: (2022)

Longitudinal Optical Coherence Tomography Angiography Findings in Malignant Hypertension Choroidopathy: A Case Report
por: Viruni, Narine, et al.
Publicado: (2022)

Oblimersen for the treatment of patients with chronic lymphocytic leukemia
por: Cheson, Bruce D
Publicado: (2007)

Role of bendamustine in the treatment of chronic lymphocytic leukemia
por: Jamshed, Saad, et al.
Publicado: (2009)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib
por: Koba, Yusuke, et al.
Publicado: (2023)

Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib
por: Christoforidou, Anna, et al.
Publicado: (2018)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)

Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
por: Molica, Stefano, et al.
Publicado: (2016)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
por: Arthurs, Benjamin, et al.
Publicado: (2017)

Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
por: Sittig, Katherine R., et al.
Publicado: (2021)

Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
por: Liu, Yanyan, et al.
Publicado: (2022)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Successful treatment of “accelerated” chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.
por: Xie, John, et al.
Publicado: (2021)

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
por: de Jong, Jan, et al.
Publicado: (2015)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
por: Okamoto, Koh, et al.
Publicado: (2016)

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
por: Landau, Dan A., et al.
Publicado: (2017)

Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy
por: Voshtina, Ensi, et al.
Publicado: (2018)

Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia
por: Beresford, Rohan, et al.
Publicado: (2019)

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2016)

Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
por: Lutz, Mathias, et al.
Publicado: (2017)

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
por: Zhou, Hong, et al.
Publicado: (2020)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
por: Hampel, Paul J., et al.
Publicado: (2022)

Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic
por: Chauhan, Ayushi F, et al.
Publicado: (2021)

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients
por: Boissard, F, et al.
Publicado: (2015)

Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: McNally, Gretchen Anne, et al.
Publicado: (2015)

COVID-19 IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN USE OF IBRUTINIB: NOT THAT RISKY?
por: Dourado, M.L.B.F., et al.
Publicado: (2020)

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
por: Al‐Katib, Ayad M., et al.
Publicado: (2020)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review
por: Sardar, Muhammad, et al.
Publicado: (2019)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report
por: Turcotte, Anna-Eve, et al.
Publicado: (2023)

Fatal Cryptococcal Meningitis in a Patient With Chronic Lymphocytic Leukemia Treated With Ibrutinib
por: Oumayma, Hari, et al.
Publicado: (2023)

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
por: Gill, Saar, et al.
Publicado: (2022)

Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature
por: Annalisa, Arcari, et al.
Publicado: (2017)

Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment
por: Guo, Ailin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t4ejunh804d4bcknkpuhd5k6fq